Merck KGaA (OTCMKTS:MKKGY) Rating Lowered to Hold at UBS Group

Merck KGaA (OTCMKTS:MKKGY) was downgraded by equities researchers at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other research firms also recently issued reports on MKKGY. Jefferies Financial Group began coverage on shares of Merck KGaA in a research note on Tuesday, May 26th. They set a “hold” rating for the company. HSBC raised shares of Merck KGaA to a “hold” rating in a research note on Monday, July 6th. Finally, Zacks Research upgraded Merck KGaA from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 22nd. Six analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

Merck KGaA Stock Up 0.6%

OTCMKTS:MKKGY opened at $32.24 on Thursday. The firm’s 50 day simple moving average is $32.23 and its 200 day simple moving average is $29.36. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.51 and a quick ratio of 1.00. Merck KGaA has a one year low of $23.73 and a one year high of $34.19. The company has a market cap of $20.83 billion, a PE ratio of 16.62, a P/E/G ratio of 2.62 and a beta of 0.98.

Merck KGaA Company Profile

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.